丁酸通过增强肝线粒体功能缓解高脂诱导的小鼠肥胖北大核心CSCD

丁酸可以预防高脂日粮诱导的小鼠肥胖和胰岛素抵抗,但是否有治疗作用尚不清楚。本研究证明,高脂日粮诱导小鼠肥胖模型后,用80 mg/mL丁酸钠水溶液灌胃能够缓解肥胖。表观指标检测发现,丁酸钠显著降低肥胖小鼠的肝重(1.24 g±0.03 g至1.08 g±0.04 g)、体重(32.46 g±0.50 g至28.35 g±0.58 g)和附睾脂重(1.33 g±0.13 g至0.81 g±0.08 g)及其与体重的比(4.06%±0.37%至2.83%±0.22%)。葡萄糖耐受实验和血液激素含量检测表明,丁酸钠部分缓解由高脂引起的葡萄糖不耐受,并显著降低血液中瘦素(3.71 ng/mL±0.62 ng/mL至1.50ng/m L±0.26 ng/mL)和胰岛素(2.39 ng/mL±0.30 ng/mL至1.25 ng/mL±0.09 ng/mL)的水平。肝中脂质和糖原的生化检测表明,丁酸钠对肝中的甘油三酯、胆固醇和糖原的含量没有显著影响。通过RT-PCR实验发现,丁酸钠显著上调线粒体β氧化和解耦联相关的关键基因以及线粒体自身编码的8个基因的mRNA水平的表达,Western印迹检测表明,丁酸钠显著升高肝葡萄糖转运蛋白GLUT2和调控线粒体功能的关键蛋白PGC-1α的表达。上述结果提示,丁酸钠可能通过增强肝线粒体功能缓解食源性小鼠肥胖。     

EPO对高脂喂养小鼠棕色脂肪组织PRDM16、FGF21表达及STAT3磷酸化水平的影响

目的：探索促红细胞生成素（EPO）对高脂饲料（HFD）喂养小鼠血糖和血浆胰岛素水平、胰岛素抵抗指数（HOMA-IR）、糖耐量,以及棕色脂肪组织中含PR结构域蛋白16（PRDM16）、信号转导与转录激活因子3（STAT3）磷酸化水平（p-STAT3/STAT3）、成纤维细胞生长因子21（FGF21）mRNA以及蛋白质表达的影响,为肥胖及其并发症的发生机制提供线索。方法：20只高脂饲料喂养的C57BL/6J雄性小鼠随机分为对照组（HFD-Con）和EPO组（HFD-EPO）,两组分别腹腔注射生理盐水和EPO（200 IU/kg）,每周3次,连续4周。4周后检测两组动物的体重、血糖与血浆胰岛素水平、HOMA-IR及糖耐量的变化;分别使用实时定量PCR法和Western blot法检测棕色脂肪组织中PRDM16、STAT3、FGF21 mRNA和蛋白质水平。结果：腹腔注射EPO 4周后,HFD-EPO组小鼠体重为（26.65±0.85）g,HFD-Con组体重为（31.50±1.60）g,P<0.01。HFD-Con组血糖为（91.06±9.86）mg/dl,HFD-EPO组为（62.79±8.09）mg/dl,P<0.01;HFD-EPO组小鼠血浆胰岛素水平为（10.56±1.06）μU/ml,HFD-Con组为（13.2±1.1）μU/ml,P<0.01。与HFD-Con组比较,HFD-EPO组的糖耐量水平显著改善,胰岛素抵抗指数下降;HFD-EPO组动物棕色脂肪组织中PRDM16、FGF21mRNA以及蛋白质表达,p-STAT/STAT3水平均显著增加,两组小鼠肝脏中FGF21 mRNA含量、血浆中FGF21含量无明显差异。结论：EPO可能通过增加棕色脂肪组织中PRDM16表达促进棕色脂肪组织的分化,降低高脂喂养小鼠的血糖水平、改善高脂喂养小鼠的糖代谢状态。     

芍药苷通过抑制脊髓Akt-NF-kB信号通路及小胶质细胞激活缓解炎症性疼痛

芍药苷具有抑制炎症和镇痛的作用，在治疗炎症疼痛方面具有重要价值，但其作用机制尚不明确。本研究发现，弗氏完全佐剂诱导小鼠炎症疼痛模型，用80 mg/kg芍药苷腹腔注射能有效缓解疼痛。检测发现芍药苷治疗后，小鼠机械性痛阈与热板痛阈均明显升高（机械性痛阈值：由6.38±1.00 g提高至8.31±0.81 g；热板痛阈值：由5.78±0.76 s提高至9.90±1.58 s）；同时抑制外周炎症因子TNF-α等的释放（由708.71±46.55 pg/mL降低至588.65±16.02 pg/mL）；免疫组织化学检测发现，芍药苷能有效抑制脊髓背角小胶质细胞的激活；NO检测结果发现，脊髓部位NO合成降低（3.55±0.28 μmol/L·g^-1Pro降至2.25±0.71 μmol/L·g^-1Pro）；Western 印迹检测证实，脊髓部位iNOS在使用芍药苷后，表达恢复正常水平。同时发现，Akt-NF-κB信号可能参与芍药苷的镇痛作用。上述结果提示，芍药苷缓解慢性炎症疼痛可通过抑制炎症因子释放，也通过抑制脊髓小胶质细胞的激活，而此过程依赖抑制Akt-NF-κB信号的激活。     

高脂食物诱导的肥胖小鼠不同脑区即刻早期蛋白和酪氨酸羟化酶的变化

目的：在高脂食物诱导肥胖的小鼠中检测多巴胺神经元的表达。方法：10只雄性小鼠饲喂高脂膳食作为高脂食物组（HFD）,10只雄性小鼠饲喂10%脂肪膳食作为对照组（NCD）。实验第10周,小鼠禁食12 h后称重,尾静脉取血测定基础血糖水平;实验11周进行葡萄糖耐受（GTT）测试和胰岛素抵抗实验（ITT）;实验12周,动物禁食4 h后处死,测定血清胰岛素和瘦素（leptin）浓度,免疫组织化学法检测即刻早期蛋白（c-Fos-ir）和酪氨酸羟化酶（TH-ir）的表达。结果：饲喂12周高脂食物后,HFD组体重明显增加。GTT测试显示HFD组在15 min和30 min血糖浓度均明显高于NCD组（P<0.05）。ITT测试显示HFD组在15 min和30 min血糖浓度均显著高于NCD组（P<0.05）。同时,禁食后,HFD组的胰岛素浓度和leptin浓度显著高于NCD组（P<0.01）。免疫组化结果表明HFD组在伏隔核、下丘脑室旁核、腹侧背盖区和黑质的c-Fos-ir细胞数均明显多于NCD组（P<0.01）,且腹侧被盖区和黑质的TH-ir和共表达TH/Fos-ir细胞也显著多于NCD组（P<0.01）。而且HFD组VTA区和SN区TH-ir的细胞数与HFD组小鼠的终体重呈正相关（P<0.05）。结论：长期饲喂高脂食物导致的肥胖与奖赏系统多巴胺神经元的可塑性有关。     

乙酸可通过增强脂肪酸β氧化治疗小鼠肥胖

目的：探讨乙酸对高脂饮食诱导的肥胖小鼠体重及脂肪酸β氧化的影响。方法：3~4w龄C57BL/6J雄性小鼠分别给予正常饲料和高脂饲料喂养4个月以诱导肥胖,然后对肥胖小鼠实施乙酸治疗5w。喂养过程结束后,心脏采血,取结肠、肝脏和性腺周围脂肪。检测血浆葡萄糖、甘油三酯（TG）、总胆固醇（TCH）和胰岛素浓度,同时检测结肠G蛋白偶联受体（GPR43、GPR41）、酪酪肽（PYY）、胰高血糖素样肽1（GLP-1）以及肝脏和脂肪肉碱脂酰转移酶（cpt）基因mRNA表达水平。结果：高脂诱导的肥胖小鼠给予乙酸治疗5w后,体重显著性下降,但日均进食量和能量摄入却显著增加（P<0.05）。肥胖小鼠的血浆葡萄糖、TG和TCH较正常小鼠,均显著升高（P<0.05）,给予乙酸治疗后,血浆TG和TCH水平均显著降低（P<0.05）。与正常小鼠相比,肥胖小鼠结肠中GPR43、GPR41、PYY和GLP1的mRNA表达量均显著性升高（P<0.05）,脂肪和肝脏中cpt1a、cpt1c、cpt2的mRNA表达显著性降低（P<0.05）;肥胖小鼠给予乙酸治疗后,结肠中上述基因mRNA表达量均显著性降低（P<0.05）,脂肪中cpt基因mRNA表达均显著性升高（P<0.05）。结论：乙酸对小鼠肥胖有较好的治疗效果,其作用机制可能是通过特异性促进脂肪组织中脂肪酸β氧化。     

桑叶黄酮调控糖尿病模型小鼠心肌线粒体功能和纤维化进展的机制

摘要 目的：研究桑叶黄酮对糖尿病小鼠心肌线粒体功能和心肌纤维化的影响,并探讨其作用的具体分子机制。方法：45只ICR小鼠,随机分为3组,即正常组、模型组和桑叶黄酮组。模型组和桑叶黄酮组通过腹腔注射四氧嘧啶生理盐水溶液建立糖尿病模型,正常组小鼠腹腔注射生理盐水。桑叶黄酮组糖尿病小鼠在模型成功建立后灌胃给予桑叶黄酮（1.0 g/kg/天）治疗,正常组和模型组给予等量生理盐水治疗。治疗6周后,测定并比较三组小鼠血糖、血胰岛素、肝糖原、肝己糖激酶（HK）和丙酮酸激酶（PK）含量,心肌线粒体谷胱甘肽（GSH）、超氧化物歧化酶（SOD）、总钙和ATP含量,以及心脏CD31、α-SMA和Collagen I mRNA表达。结果：研究期间,模型组和桑叶黄酮组小鼠分别死亡3只和1只。经桑叶黄酮治疗6周后,糖尿病小鼠血糖显著降低,血胰岛素水平、肝糖原、肝HK和肝PK含量,心肌线粒体GSH、SOD、总钙和ATP含量均显著增高（P<0.05）。心肌纤维化指标：糖尿病小鼠心肌CD31 mRNA表达水平经桑叶黄酮治疗后显著增高,而α-SMA和Collagen I mRNA表达水平却显著降低（P<0.05）。结论：桑叶黄酮可显著降低糖尿病小鼠血糖水平,改善其糖代谢和心肌线粒体损伤,延缓心肌纤维化进展。     

有氧运动激活肥胖大鼠前额叶PPARγ-PI3K-Akt通路并促进神经可塑性相关蛋白表达

采用高脂饮食建立肥胖大鼠模型,使用Western印迹检测大鼠前额叶PPARγ- PI3K-Akt通路及神经可塑性相关蛋白质表达,明确高脂饮食诱导肥胖后对大鼠前额叶神经可塑性影响及观察有氧运动的调节作用。结果表明,与对照组（CS）相比,高脂饮食肥胖大鼠（OS）前额叶过氧化物酶体增殖剂激活受体（PPARγ）（0.46±0.07 vs. 0.81±0.09, P<0.01）、p-PI3K/PI3K（0.21±0.04 vs. 0.36±0.03, P<0.05）与p-Akt/Akt（0.22±0.04 vs. 0.33±0.05, P<0.05）比值、脑源性神经生长因子（BDNF）（0.71±0.08 vs. 1.06±0.10, P<0.01）及突触素（SYN）（0.18±0.03 vs. 0.36±0.03, P<0.01）表达均显著下降;凋亡相关蛋白质胱天蛋白酶9（0.37±0.05 vs. 0.18±0.01, P<0.01）表达及Bax/Bcl-2（2.95±0.73 vs. 0.94±0.18, P<0.01）比值显著升高。有氧运动后,与安静肥胖组(OS)相比,肥胖运动组(OE)大鼠前额叶PPARγ（0.65±0.11 vs. 0.46±0.07, P<0.05）、p-PI3K/PI3K（0.33±0.06 vs. 0.21±1.04, P<0.05）与p-Akt/Akt（0.31±0.05 vs. 0.22±0.04, P<0.05）比值显著上调;胱天蛋白酶9（0.22±0.04 vs. 0.37±0.05, P<0.05）及Bax/Bcl-2（1.74±0.43 vs. 2.95±0.43 P<0.05）比值显著下调。但是,BDNF（0.92±0.16 vs. 0.71±0.08）及SYN（0.30±0.04 vs. 0.18±0.03）表达无显著差异。结果提示,高脂饮食可导致肥胖大鼠前额叶神经可塑性相关蛋白质表达下降,其机制可能与神经细胞凋亡的发生有关。有氧运动可通过激活PPAR-γ-PI3K-Akt通路途径抑制细胞凋亡的发生,促进神经可塑性相关蛋白质的表达。     

白藜芦醇对高脂饲养小鼠脂肪组织氧化还原状态及血脂的影响

本研究旨在探索白藜芦醇(RSV)对不同程度肥胖小鼠脂肪氧化应激状态和血脂的影响。高脂日粮(HFD)处理12周的昆明小鼠分为3类:肥胖抵抗(DIO-R)、中体重(Med)和肥胖(DIO),分别饲喂HFD、HFD+0.3 g/kg RSV和HFD+0.6 g/kg RSV日粮18周,并以正常日粮小鼠为对照。结果表明,0.6 g/kg RSV处理可显著降低DIO小鼠体重、腹脂率,显著提高脂肪组织抗氧化能力,改善血脂。0.3 g/kg RSV处理对DIO-R小鼠也有类似趋势,但0.6 g/kg RSV处理引起DIO-R小鼠脂肪组织抗氧化能力下降、血脂紊乱。总之,RSV在不同程度肥胖小鼠具有剂量特异性的氧化应激调控作用。     

脂联素改善阿尔茨海默病模型小鼠焦虑情绪及工作记忆

目的：探讨脂联素（APN）预处理对9月龄三转基因阿尔茨海默病（3xTg-AD）模型小鼠学习记忆能力和焦虑情绪的影响。方法：选取9月龄3xTg-AD小鼠及C57BL/6J小鼠,分为4组：WT+Saline组、3xTg-AD+Saline组、WT+APN组和3xTg-AD+APN组,每组8只。将全部小鼠进行侧脑室埋管术后,恢复7 d,在自由清醒状态下分别经侧脑室给予生理盐水或APN,采用旷场、新物体识别及Y-迷宫3种行为学手段检测小鼠的情绪及学习记忆能力。结果：①在旷场实验中,与WT+Saline组小鼠相比,3xTg-AD+Saline组小鼠在中央区域的活动时间明显缩短,在外周区域的活动时间明显延长,给予APN后可有效逆转3xTg-AD小鼠的该现象,表明脂联素可有效缓解3xTg-AD小鼠的焦虑情绪。②新物体识别实验中,3xTg-AD+Saline组小鼠的辨别指数为（-16.7±10.1）%,明显低于WT+Saline组的（18.0±8.2）%（P<0.01）和3xTg-AD+APN组的（15.7±8.8）%（P<0.01）,表明脂联素可明显改善3xTg-AD小鼠的识别记忆能力损伤。③Y-迷宫实验中,3xTg-AD+Saline组小鼠的自发交替正确率为（40.0±1.7）%,明显低于WT+Saline组的（56.6±4.6）%（P<0.01）和3xTg-AD+APN组的（53.9±5.6）%（P<0.01）,表明脂联素能够逆转3xTg-AD小鼠工作记忆能力的损伤。结论：脂联素可以改善9月龄3xTg-AD小鼠的焦虑情绪及识别记忆和工作记忆能力损伤,可能在AD的预防和治疗中发挥有效作用。     

圈养马麝刻板行为表达与粪样类固醇激素的关系

2017年7月1日-8月31日及2018年6月1日-7月31日,在甘肃兴隆山保护区马麝繁育中心,采用焦点取样法和连续记录法进行了圈养马麝的刻板行为取样,采集同期粪样,并用放射免疫分析法（RIA）检测粪样中肾上腺皮质醇、睾酮及雌二醇激素的水平,分析了圈养马麝刻板行为表达与上述3种激素水平的关系。结果显示,展现刻板行为的圈养马麝的皮质醇水平（111.099 ± 16.231）ng/g略高于无刻板行为表达的马麝（95.640± 9.738） ng/g,差异未达显著（P> 0.05）;展现刻板行为雄麝的睾酮水平（135.900± 21.582）ng/g略高于无刻板行为的雄麝（108.182 ± 9.689） ng/g,差异也不显著（P> 0.05）;展现刻板行为雌麝的雌二醇水平（0.445 ± 0.116）ng/g显著低于无刻板行为雌麝（10.843 ± 1.142）ng/g（P< 0.05）。研究结果表明,圈养雄性马麝的刻板行为表达与其类固醇激素水平不相关;而雌麝的刻板行为表达与雌二醇分泌显著负相关,这与其繁殖及健康状况有关。在麝类驯养实践中,可将粪样类固醇激素水平（尤其是雌二醇）作为其受胁迫水平及行为健康的监测指标。     

Sub-chronic administration of the 11beta-HSD1 inhibitor, carbenoxolone, improves glucose tolerance and insulin sensitivity in mice with diet-induced obesity

We have examined the metabolic effects of daily administration of carbenoxolone (CBX), a naturally occurring 11beta-hydroxysteroid dehydrogenase (11beta-HSD1) inhibitor, in mice with high fat diet-induced insulin resistance and obesity. Eight-week-old male Swiss TO mice placed on a synthetic high fat diet received daily intraperitoneal injections of either saline vehicle or CBX over a 16-day period. Daily administration of CBX had no effect on food intake, but significantly lowered body weight (1.1- to 1.2-fold) compared to saline-treated controls. Non-fasting plasma glucose levels were significantly decreased (1.6-fold) by CBX treatment on day 4 and remained lower throughout the treatment period. Circulating plasma corticosterone levels were not significantly altered by CBX treatment. Plasma glucose concentrations of CBX-treated mice were significantly reduced (1.4-fold) following an intraperitoneal glucose load compared with saline controls. Similarly, after 16-day treatment with CBX, exogenous insulin evoked a significantly greater reduction in glucose concentrations (1.4- to 1.8-fold). 11beta-HSD1 gene expression was significantly down-regulated in liver, whereas glucocorticoid receptor gene expression was increased in both liver and adipose tissue following CBX treatment. The reduced body weight and improved metabolic control in mice with high fat diet-induced obesity upon daily CBX administration highlights the potential value of selective 11beta-HSD1 inhibition as a new route for the treatment of type 2 diabetes and obesity.     

Loss of FXR protects against diet-induced obesity and accelerates liver carcinogenesis in ob/ob mice

Farnesoid X receptor (FXR) is known to play important regulatory roles in bile acid, lipid, and carbohydrate metabolism. Aged (>12 months old) Fxr(-/-) mice also develop spontaneous liver carcinomas. In this report, we used three mouse models to investigate the role of FXR deficiency in obesity. As compared with low-density lipoprotein receptor (Ldlr) knockout (Ldlr(-/-)) mice, the Ldlr(-/-)Fxr(-/-) double-knockout mice were highly resistant to diet-induced obesity, which was associated with increased expression of genes involved in energy metabolism in the skeletal muscle and brown adipose tissue. Such a striking effect of FXR deficiency on obesity on an Ldlr(-/-) background led us to investigate whether FXR deficiency alone is sufficient to affect obesity. As compared with wild-type mice, Fxr(-/-) mice showed resistance to diet-induced weight gain. Interestingly, only female Fxr(-/-) mice showed significant resistance to diet-induced obesity, which was accompanied by increased energy expenditure in these mice. Finally, we determined the effect of FXR deficiency on obesity in a genetically obese and diabetic mouse model. We generated ob(-/-)Fxr(-/-) mice that were deficient in both Leptin and Fxr. On a chow diet, ob(-/-)Fxr(-/-) mice gained less body weight and had reduced body fat mass as compared with ob/ob mice. In addition, we observed liver carcinomas in 43% of young (<11 months old) Ob(-/-)Fxr(-/-) mice. Together these data indicate that loss of FXR prevents diet-induced or genetic obesity and accelerates liver carcinogenesis under diabetic conditions.     

Altered glutathione homeostasis in heart augments cardiac lipotoxicity associated with diet-induced obesity in mice

Obesity-related cardiac lipid accumulation is associated with increased myocardial oxidative stress. The role of the antioxidant glutathione in cardiac lipotoxicity is unclear. Cystathionine β-synthase (Cbs) catalyzes the first step in the trans-sulfuration of homocysteine to cysteine, which is estimated to provide ～50% of cysteine for hepatic glutathione biosynthesis. As cardiac glutathione is a reflection of the liver glutathione pool, we hypothesize that mice heterozygous for targeted disruption of Cbs (Cbs(+/-)) are more susceptible to obesity-related cardiolipotoxicity because of impaired liver glutathione synthesis. Cbs(+/+) and Cbs(+/-) mice were fed a high fat diet (60% energy) from weaning for 13 weeks to induce obesity and had similar increases in body weight and body fat. This was accompanied by increased hepatic triglyceride but no differences in hepatic glutathione levels compared with mice fed chow. However, Cbs(+/-) mice with diet-induced obesity had greater glucose intolerance and lower total and reduced glutathione levels in the heart, accompanied by lower plasma cysteine levels compared with Cbs(+/+) mice. Higher triglyceride concentrations, increased oxidative stress, and increased markers of apoptosis were also observed in heart from Cbs(+/-) mice with diet-induced obesity compared with Cbs(+/+) mice. This study suggests a novel role for Cbs in maintaining the cardiac glutathione pool and protecting against cardiac lipid accumulation and oxidative stress during diet-induced obesity in mice.     

Comparison of the obesity phenotypes related to monosodium glutamate effect on arcuate nucleus and/or the high fat diet feeding in C57BL/6 and NMRI mice

In this study, susceptibility of inbred C57BL/6 and outbred NMRI mice to monosodium glutamate (MSG) obesity or diet-induced obesity (DIO) was compared in terms of food intake, body weight, adiposity as well as leptin, insulin and glucose levels. MSG obesity is an early-onset obesity resulting from MSG-induced lesions in arcuate nucleus to neonatal mice. Both male and female C57BL/6 and NMRI mice with MSG obesity did not differ in body weight from their lean controls, but had dramatically increased fat to body weight ratio. All MSG obese mice developed severe hyperleptinemia, more remarkable in females, but only NMRI male mice showed massive hyperinsulinemia and an extremely high HOMA index that pointed to development of insulin resistance. Diet-induced obesity is a late-onset obesity; it developed during 16-week-long feeding with high-fat diet containing 60 % calories as fat. Inbred C57BL/6 mice, which are frequently used in DIO studies, both male and female, had significantly increased fat to body weight ratio and leptin and glucose levels compared with their appropriate lean controls, but only female C57BL/6 mice had also significantly elevated body weight and insulin level. NMRI mice were less prone to DIO than C57BL/6 ones and did not show significant changes in metabolic parameters after feeding with high-fat diet.     

Butyrate and propionate protect against diet-induced obesity and regulate gut hormones via free fatty acid receptor 3-independent mechanisms

Short-chain fatty acids (SCFAs), primarily acetate, propionate, and butyrate, are metabolites formed by gut microbiota from complex dietary carbohydrates. Butyrate and acetate were reported to protect against diet-induced obesity without causing hypophagia, while propionate was shown to reduce food intake. However, the underlying mechanisms for these effects are unclear. It was suggested that SCFAs may regulate gut hormones via their endogenous receptors Free fatty acid receptors 2 (FFAR2) and 3 (FFAR3), but direct evidence is lacking. We examined the effects of SCFA administration in mice, and show that butyrate, propionate, and acetate all protected against diet-induced obesity and insulin resistance. Butyrate and propionate, but not acetate, induce gut hormones and reduce food intake. As FFAR3 is the common receptor activated by butyrate and propionate, we examined these effects in FFAR3-deficient mice. The effects of butyrate and propionate on body weight and food intake are independent of FFAR3. In addition, FFAR3 plays a minor role in butyrate stimulation of Glucagon-like peptide-1, and is not required for butyrate- and propionate-dependent induction of Glucose-dependent insulinotropic peptide. Finally, FFAR3-deficient mice show normal body weight and glucose homeostasis. Stimulation of gut hormones and food intake inhibition by butyrate and propionate may represent a novel mechanism by which gut microbiota regulates host metabolism. These effects are largely intact in FFAR3-deficient mice, indicating additional mediators are required for these beneficial effects.     

Tributyrin attenuates obesity-associated inflammation and insulin resistance in high-fat-fed mice

The aim of this study was to investigate whether treatment with tributyrin (Tb; a butyrate prodrug) results in protection against diet-induced obesity and associated insulin resistance. C57BL/6 male mice fed a standard chow or high-fat diet were treated with Tb (2 g/kg body wt, 10 wk) and evaluated for glucose homeostasis, plasma lipid profile, and inflammatory status. Tb protected mice against obesity and obesity-associated insulin resistance and dyslipidemia without food consumption being affected. Tb attenuated the production of TNFα and IL-1β by peritoneal macrophages and their expression in adipose tissue. Furthermore, in the adipose tissue, Tb reduced the expression of MCP-1 and infiltration by leukocytes and restored the production of adiponectin. These effects were associated with a partial reversion of hepatic steatosis, reduction in liver and skeletal muscle content of phosphorylated JNK, and an improvement in muscle insulin-stimulated glucose uptake and Akt signaling. Although part of the beneficial effects of Tb are likely to be secondary to the reduction in body weight, we also found direct protective actions of butyrate reducing TNFα production after LPS injection and in vitro by LPS- or palmitic acid-stimulated macrophages and attenuating lipolysis in vitro and in vivo. The results, reported herein, suggest that Tb may be useful for the treatment and prevention of obesity-related metabolic disorders.     

Mice Lacking C1q Are Protected from High Fat Diet-induced Hepatic Insulin Resistance and Impaired Glucose Homeostasis

Complement activation is implicated in the development of obesity and insulin resistance, and loss of signaling by the anaphylatoxin C3a prevents obesity-induced insulin resistance in mice. Here we have identified C1q in the classical pathway as required for activation of complement in response to high fat diets. After 8 weeks of high fat diet, wild-type mice became obese and developed glucose intolerance. This was associated with increased apoptotic cell death and accumulation of complement activation products (C3b/iC3b/C3c) in liver and adipose tissue. Previous studies have shown that high fat diet-induced apoptosis is dependent on Bid; here we report that Bid-mediated apoptosis was required for complement activation in adipose and liver. Although C1qa deficiency had no effect on high fat diet-induced apoptosis, accumulation of complement activation products and the metabolic complications of high fat diet-induced obesity were dependent on C1q. When wild-type mice were fed a high fat diet for only 3 days, hepatic insulin resistance was associated with the accumulation of C3b/iC3b/C3c in the liver. Mice deficient in C3a receptor were protected against this early high fat diet-induced hepatic insulin resistance, whereas mice deficient in the negative complement regulator CD55/DAF were more sensitive to the high fat diet. C1qa^−/− mice were also protected from high fat diet-induced hepatic insulin resistance and complement activation. Evidence of complement activation was also detected in adipose tissue of obese women compared with lean women. Together, these studies reveal an important role for C1q in the classical pathway of complement activation in the development of high fat diet-induced insulin resistance.     

Ipragliflozin Improves Hepatic Steatosis in Obese Mice and Liver Dysfunction in Type 2 Diabetic Patients Irrespective of Body Weight Reduction

Type 2 diabetes mellitus (T2DM) is associated with a high incidence of non-alcoholic fatty liver disease (NAFLD) related to obesity and insulin resistance. Currently, medical interventions for NAFLD have focused on diet control and exercise to reduce body weight, and there is a requirement for effective pharmacological therapies. Sodium-glucose cotransporter 2 (SGLT2) inhibitors are oral antidiabetic drugs that promote the urinary excretion of glucose by blocking its reabsorption in renal proximal tubules. SGLT2 inhibitors lower blood glucose independent of insulin action and are expected to reduce body weight because of urinary calorie loss. Here we show that an SGLT2 inhibitor ipragliflozin improves hepatic steatosis in high-fat diet-induced and leptin-deficient (ob/ob) obese mice irrespective of body weight reduction. In the obese mice, ipragliflozin-induced hyperphagia occurred to increase energy intake, attenuating body weight reduction with increased epididymal fat mass. There is an inverse correlation between weights of liver and epididymal fat in ipragliflozin-treated obese mice, suggesting that ipragliflozin treatment promotes normotopic fat accumulation in the epididymal fat and prevents ectopic fat accumulation in the liver. Despite increased adiposity, ipragliflozin ameliorates obesity-associated inflammation and insulin resistance in epididymal fat. Clinically, ipragliflozin improves liver dysfunction in patients with T2DM irrespective of body weight reduction. These findings provide new insight into the effects of SGLT2 inhibitors on energy homeostasis and fat accumulation and indicate their potential therapeutic efficacy in T2DM-associated hepatic steatosis.     

Effects of aqueous extract of Portulaca oleracea L. on oxidative stress and liver, spleen leptin, PARα and FAS mRNA expression in high-fat diet induced mice

We reported that an aqueous extract of Portulaca oleracea L. inhibited high-fat-diet-induced oxidative injury in a dose-dependent manner. Male kunming mice (5-weeks-old, 24 g) were used in this experiment. After a 4-day adaptation period, animals were randomly divided into four groups (n = 10 in each group); Group 1: animals received normal powdered rodent diet; Group 2: animals received high fat diet; Groups 3 and 4: animals received high fat diet and were fed by gavage to mice once a day with aqueous extract at the doses of 100 and 200 mg/kg body weight, respectively. In mice fed with high-fat diet, blood and liver lipid peroxidation level was significantly increased, whereas antioxidant enzymes activities were markedly decreased compared to normal control mice. Administration of an aqueous extract of P. oleracea L. significantly dose-dependently reduced levels of blood and liver lipid peroxidation and increased the activities of blood and liver antioxidant enzymes activities in high fat mice. Moreover, administration of an aqueous extract of P. oleracea L. significantly dose-dependently increase liver Leptin/β-actin (B), and Liver PPARα/β-actin, decrease liver, spleen FAS mRNA, p-PERK and p-PERK/PERK protein expression levels. Taken together, these data demonstrate that aqueous extract of P. oleracea L. can markedly alleviate high fat diet-induced oxidative injury by enhancing blood and liver antioxidant enzyme activities, modulating Leptin/β-actin (B), and Liver PPARα/β-actin, decrease liver, spleen FAS mRNA, p-PERK and p-PERK/PERK protein expression levels in mice.     

Beta-arrestin-1 protein represses diet-induced obesity

Diet-related obesity is a major metabolic disorder. Excessive fat mass is associated with type 2 diabetes, hepatic steatosis, and arteriosclerosis. Dysregulation of lipid metabolism and adipose tissue function contributes to diet-induced obesity. Here, we report that β-arrestin-1 knock-out mice are susceptible to diet-induced obesity. Knock-out of the gene encoding β-arrestin-1 caused increased fat mass accumulation and decreased whole-body insulin sensitivity in mice fed a high-fat diet. In β-arrestin-1 knock-out mice, we observed disrupted food intake and energy expenditure and increased macrophage infiltration in white adipose tissue. At the molecular level, β-arrestin-1 deficiency affected the expression of many lipid metabolic genes and inflammatory genes in adipose tissue. Consistently, transgenic overexpression of β-arrestin-1 repressed diet-induced obesity and improved glucose tolerance and systemic insulin sensitivity. Thus, our findings reveal that β-arrestin-1 plays a role in metabolism regulation.